Literature DB >> 9182021

Providing cost-effective therapy using pharmacoeconomic evaluations: the public sector approach.

S Finder.   

Abstract

Four years ago it became obvious within the US Department of Defense (DOD) that expenditures for pharmaceuticals and health care were escalating beyond control. Realizing this upward pressure on costs was one of the major trends jeopardizing the military health care system, which cares for 8 million-plus beneficiaries, the DOD began using pharmacoeconomics to manage pharmacy expenditures. The DOD has several competing goals: to reduce pharmaceutical expenditures within the context of an open formulary while maintaining optimum patient care; provide practitioners, pharmacists, and administrators with the information they need to make cost-effective choices in pharmacotherapy; and provide for a consistent and equitable pharmacy benefit throughout the DOD based on cost-effective recommendations. Currently used methods for pharmacoeconomics did not meet the DOD's needs, so it turned to applied pharmacoeconomics. This paper discusses the use of applied pharmacoeconomics as it pertains to the DOD.

Entities:  

Mesh:

Year:  1997        PMID: 9182021     DOI: 10.1016/s0149-2918(97)80083-5

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  1 in total

1.  The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals.

Authors:  J L Glennie; G W Torrance; J F Baladi; C Berka; E Hubbard; D Menon; N Otten; M Rivière
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.